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Abstract 
The MET pathway plays a key role in various cancers, and its inhibition represents a potential 
treatment target. However, appropriate biomarkers are needed to facilitate the selection of 
patients who would benefit from MET inhibiting therapy. We herein conducted a robust 
confirmatory evaluation of the MET copy number alteration status and prognostic significance of 
c-Met expression in a large series of patients (n = 396) who underwent standard surgical resection 
and adjuvant chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC). Surgically 
resected HNSCC samples were subjected to immunohistochemical and H-score analysis of c-Met 
expression and silver in situ hybridization analysis of MET amplification and copy number gains. 
c-Met expression varied, with mean and median H-scores (scale: 0–300 scale) of 61.2 and 60.0, 
respectively. The lowest and highest expression levels were observed in SCC of the larynx and 
oral cavity, respectively. MET copy number gains were observed in 16.9% of cases (67/339) and 
were associated with c-Met protein expression. High c-Met expression, determined according to 
MET gain status, was associated with an inferior overall survival rate, especially among completely 
resected cases. In conclusion, our robust analysis revealed that c-Met expression in HNSCCs 
varied according to anatomical site, correlated with MET copy number gains, and was associated 
with poor prognosis. This c-Met expression analysis method, which is based on the MET gain 
status, appears to appropriately predict high-risk HNSCC patients in the context of anti-MET 
therapeutic decisions. 
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Introduction 
Head and neck cancers (HNCs) comprise one of 
the most common groups of cancers worldwide. 
Histologically, approximately 95% of all HNCs are 
head and neck squamous cell carcinoma (HNSCC) [1]; 
this type of tumor is characterized by frequent 
recurrence and metastasis, as well as resistance to the 
conventional cisplatin-based chemoradiotherapy. 
Accordingly, patients with recurrent or metastatic 
HNSCC have dismal outcomes [2]. 
The tyrosine kinase receptor c-Met normally 
binds with hepatocyte growth factor (HGF), which 
triggers its involvement in processes such as 
embryogenesis, cell growth, cell differentiation, and 
angiogenesis [3, 4]. However, c-Met activation is also 
involved in processes related to malignant 
transformation, such as tumor growth, invasion, 
metastasis, and angiogenesis [5-9]. In addition to 
paracrine or autocrine signaling via HGF, c-Met may 
also be activated via protein overexpression or the 
amplification, mutation, or transcriptional alteration 
(via microRNA-mediated dysregulation) of MET 
[10-12]. c-Met overexpression and/or MET 
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amplification are known to correlate with a worse 
prognosis in some types of cancers, including 
non-small-cell lung cancer and gastric cancer [12]. In 
HNSCC, c-Met expression has been associated with 
cisplatin resistance and a strong metastatic ability in 
vivo, [2] as well as a poor patient prognosis [13]. 
 Inhibition of the MET pathway, which plays a 
key role in various types of cancer, is a potential 
cancer treatment target. Recently, several types of 
inhibitors that target various components of the MET 
signaling pathway have been introduced [12, 14-16]. 
Of these, an anti-MET monoclonal antibody has 
yielded promising results against tumors that over 
express c-Met, as have small molecule inhibitors 
against tumors harboring MET mutation or 
amplification [12]. However, a biomarker that would 
facilitate patient selection with respect to MET 
inhibiting therapy is needed.  
The prognostic significance of c-Met expression 
has not yet been confirmed in studies of MET and 
HNSCC [13, 17-19], possibly because of variability in 
detection methods and patient selection and a lack of 
validation of cut-off values. In addition, MET 
amplification and/or copy number alteration have 
been rarely studied in HNSCC; to date, a relatively 
small number of cases of recurrent/metastatic 
HNSCC at limited anatomical sites have been studied 
using immunohistochemistry and fluorescence in situ 
hybridization [13, 17-19]. Accordingly, in this study, 
we conducted a robust evaluation of c-Met expression 
and MET copy number alteration in a large number of 
patients with HNSCC at various anatomic sites of the 
head and neck who had undergone standard surgical 
resection and adjuvant chemoradiotherapy when 
indicated. In these patients, we analyzed the 
association of c-Met expression with MET copy 
alterations, as well as the associations of c-Met/MET 
abnormalities with clinical variables such as 
anatomical site, tumor-node-metastasis (TNM) stage, 
human papillomavirus (HPV) status, and survival. 
Materials and methods 
Patients and clinical data 
This study was approved by the Institutional 
Review Board of Severance Hospital. Formalin-fixed, 
paraffin-embedded specimens were obtained from 
consecutive patients who underwent surgical 
resection with a curative aim for HNSCC at Severance 
Hospital, Seoul, Korea, between 2005 and 2012 and 
were archived. The present study excluded HNSCC 
tissue samples that had been subjected to 
decalcification for accurate immunohistochemistry 
and DNA in situ hybridization analyses; as a result, 
some cases of surgically resected 
hypopharyngeal/laryngeal and sinonasal SCC were 
excluded. The inclusion criteria were available tumor 
tissue, clinical data regarding smoking status, and 
survival data; lack of preoperative treatment; and no 
clinicopathologic evidence of distant metastasis at the 
time of surgery. Ultimately, 396 cases were selected, 
among which 305 achieved complete R0 resection, 
defined histologically as tumor-free resection 
margins. In the present cohort, the affected anatomic 
sites included the oral cavity (anterior two-thirds of 
the tongue, mouth floor, hard palate, buccal mucosa, 
oral cavity; n = 204), hypopharynx (n = 28), larynx 
(lingual surface of the epiglottis, glottis, supraglottis, 
subglottis, larynx; n = 42), and oropharynx (tonsils, 
base of tongue, soft palate, oropharynx; n = 122). 
Other evaluated parameters included tumor location 
and size, histologic grade, metastasis to regional 
lymph nodes, lymphovascular invasion, and 
perineural invasion.  
Tumors were classified according to the Seventh 
American Joint Committee on Cancer (AJCC) TNM 
cancer classification system and the World Health 
Organization system [20, 21]. Two pathologists 
(S.O.Y. and Y.A.C.) confirmed the histopathologic 
diagnoses of HNSCC. Clinical data were collected 
from the patients’ medical records and reviewed to 
evaluate the clinicopathologic characteristics and 
survival outcomes. The median follow-up period was 
37.1 months (range, 0.8–99.6 months). Other 
clinicopathologic characteristics are described in 
Table 1.  
Tissue microarray preparation  
Sections of formalin-fixed, paraffin-embedded 
tissues were prepared and stained with hematoxylin 
and eosin (H&E). Representative tumor areas were 
confirmed microscopically, selected, and used for 
tissue microarray (TMA) construction. Two or three 
different representative areas per case were selected; 
core tissues (3 mm in diameter) were taken from the 
individual tissue blocks (donor blocks) and arranged 
in recipient paraffin blocks (tissue array blocks) using 
a trephine apparatus.  
Immunohistochemistry and analysis 
Immunohistochemistry was performed on 4-μm 
TMA tissue sections with a Ventana Bench Mark XT 
Autostainer (Ventana Medical Systems, Tucson, AZ, 
USA) as described in previous reports [22]. The 
following primary antibodies were tested: c-Met 
(pre-dilution; clone SP44; Ventana) and p16 (RTU; 
Ventana). c-Met protein expression was analyzed 
according to the semiquantitative H-score method; 
this method yields a total score range of 0–300 [23] by 
multiplying the dominant nuclear staining intensity 
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score (0, no staining; 1, weak or barely detectable 
membranous staining; 2, distinct brown membranous 
staining; 3, strong dark brown membranous staining) 
by the percentage (0–100%) of positive cell nuclei 
(Figs. 1A–D). Conventionally accepted criteria were 
used for p16 immunohistochemistry, and positivity 
was defined as the presence of strong and diffuse 
nuclear and cytoplasmic staining in >70% of the 
HNSCC cells. All other staining patterns were scored 
as negative [24]. 
 
Table 1. Clinicopathological characteristics of 396 HNSCC 
patients. 
Category Variables No. of cases  
(n = 396) 
Percentage 
(%) 
Sex Male 298  75.3 
 Female 98 24.7 
Age Median (IQR), yrs 58 (22-88)  
Smoking Never smoker 154 38.9 
 Ex-smoker 80 20.2 
 Current smoker 162 40.9 
Anatomical site Oral cavity 204 51.5 
 Oropharynx 122 30.8 
 Hypopharynx  28 7.1 
 Larynx 42 10.6 
p16 IHC status Negative 236 59.6 
 Positive 160 40.4 
Lymphovascular invasion Absent 320 80.8 
 Present 76 19.2 
Perineural invasion Absent 342 86.4 
 Present 54 13.6 
Resection margin status R0* 305 77.0 
 Non-R0 91 23.0 
Pathologic T stage pT1-2 326 82.3 
 pT3-4 70 17.7 
Pathologic N stage pN0-1 248 62.6 
 pN2-3 148 37.4 
Postoperative therapy No treatment 145 36.6 
 RTx alone 150 37.9 
 CCRT 99 25.0 
 CTx alone or other CTx 
alone or incomplete 
CCRT 
2 0.5 
Recurrence/metastasis Absent 293 74.0 
 Present 103 26.0 
Survival Alive 324 81.8 
 Expired 72 18.2 
HNSCC: head and neck squamous cell carcinoma; IQR: interquartile range; IHC: 
immunohistochemistry. 
* R0 resection status was defined as complete tumor resection. 
 
Dual-color silver in situ hybridization and 
interpretation (SISH) 
Dual-color SISH was performed on a Ventana 
BenchMark XT apparatus (Ventana Medical Systems) 
using the MET DNA (Roche-Ventana) and 
Chromosome 7 enumeration (CEP7) probes 
(Roche-Ventana). Signals were enumerated in 100 
tumor cells with intact, non-overlapping nuclei per 
core under a light microscope with a magnification of 
600X. Tumor nuclei with clearly distinct color signals 
for MET (black signal) and CEP7 (red signal) were 
evaluated (Figs. 1 E–H). If clusters of dots 
representing many copies of MET gene were noted, 
small and large clusters of multiple signals were 
counted as 6 and 12 signals, respectively, according to 
the interpretive guide provided for INFORM HER2 
DNA probe staining of breast carcinoma (Ventana 
Medical Systems). MET SISH results were interpreted 
by two experienced evaluators (S.O.Y. and Y.A.C.) 
blinded to the clinical data. 
To define MET copy number gain or 
amplification, several criteria were considered with 
reference to previous fluorescence in situ 
hybridization-based studies of tyrosine kinase 
receptor genes, including the University of Colorado 
Cancer Center (UCCC) criteria for the epidermal 
growth factor receptor gene [25] and criteria for the 
fibroblast growth factor receptor gene in HNSCC [26] 
and MET in several tumor types [18, 19, 27-29]. To 
address tyrosine kinase receptor gene heterogeneity 
in tumors [30], the proportion of tumor cells 
harboring copy number alterations was also 
considered. Previous studies that used the SISH 
method to detect MET copy number changes in 
several types of cancer (e.g., colorectal, gastric, 
non-small-cell lung, HNSCC) used different criteria 
for MET amplification, high MET copy numbers, and 
copy number gains. For example, MET 
amplification/copy number gain/polysomy was 
defined as a copy number ≥ 4 or ≥ 5, and the 
proportion of tumor cells (10%, 40%, or 90%, 
according to polysomy status) exhibiting copy 
number alterations was also considered in some 
definitions of MET gene amplification/copy number 
gain/polysomy [19, 31-33].  
In our study, we used the following definitions 
of MET copy number gain and amplification: 2–4 MET 
signals per nucleus in ≥20% of tumor cells, and ≥5 
MET signals per nucleus in ≥20% of tumor cells, 
respectively.  
In all 396 cases, immunohistochemistry (IHC) 
and SISH were performed. Although c-Met IHC was 
available for all cases, we were not able to properly 
evaluate several SISH cores due to either disruption of 
cores or inadequate hybridization. Therefore, after 
excluding these cases (n=59), only 339 cases of SISH 
were analyzed properly. 
Statistical analysis 
 The Mann–Whitney (MW) U test, 
Kruskal–Wallis (KW) test, one-way analysis of 
variance (ANOVA), two-sample t test, x2 test, and 
Pearson’s or Spearman’s correlation test were used to 
analyze differences between the evaluated variables. 
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Overall survival was measured from the date of initial 
diagnosis to that of death or the last follow-up visit. 
Progression-free survival was measured from the date 
of initial diagnosis to that of disease progression, 
defined as cancer recurrence, continuance of stable 
disease/partial remission/progressive disease 
without complete remission, or cancer-related death 
during the study period. The Kaplan–Meier method 
was used to analyze survival rates, and differences 
were compared using the log-rank test. The Cox 
proportional hazards model was implemented for a 
multivariate analysis. Two-sided P-values <0.05 were 
considered statistically significant. Statistical analyses 
were conducted using IBM SPSS 22 software for 
Windows (IBM Corp, Armonk, NY, USA). 
 
 
Figure 1. Immunohistochemical analysis of c-MET protein expression and silver in-situ hybridization (SISH) to determine MET copy number alterations. 
Representative images of immunohistochemical staining for c-Met demonstrate negative staining (intensity score 0, A), weak or barely detectable membranous staining (intensity 
score 1, B), distinct brown membranous staining (intensity score 2, C), and strong dark brown membranous staining (intensity score 3, D). Each intensity score was multiplied 
by the percentage of positive nuclear cell staining (0-100%) to calculate the H-score (possible scores: 0–300). In a SISH dataset, the black signals indicate MET copies and red 
signals indicate CEP7. The representative case harbored 3–4 MET signals per nucleus in ≥20% of counted tumor cells, indicating a MET copy number gain. Arrows point to cells 
that show 4 MET signals in the nucleus (E). Another representative case exhibits normal disomy of the MET and CEP7 signals (F). Selective magnification of cells is shown inside 
the black box (E and F). 
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Figure 2. Relationships of c-Met expression with affected anatomic site 
and MET copy number. The c-MET expression levels were lowest and highest in 
laryngeal squamous cell carcinoma (SCC) and SCC of the oral cavity, respectively (A). 
Intermediate c-Met levels were observed in oropharyngeal and hypopharyngeal SCC 
(P = 0.003). The c-MET protein expression level was higher in cases exhibiting MET 
copy number gains than in those without MET gains (B, P = 0.002). A receiver 
operating characteristic curve analysis based on the MET copy number gain was 
conducted to determine the c-Met protein expression cut-off value (C). 
Results 
Expression of c-Met protein in HNSCC 
 Overall, c-Met protein expression varied among 
HNSCC cases, with H-scores ranging from 0–240 
(mean and median H-scores: 61.2 and 60.0, 
respectively). Regarding anatomical sites, the lowest 
and highest expression levels were observed in 
laryngeal SCC and SCC of the oral cavity, 
respectively; oropharyngeal and hypopharyngeal 
SCCs exhibited intermediate levels of expression (P = 
0.003; Fig. 2A). Other clinicopathologic variables such 
as age, sex, smoking, lymphovascular invasion, 
perineural invasion, pT stage, and pN stage did not 
differ significantly with respect to c-Met expression 
level. 
MET copy number variation in HNSCC 
 The median MET copy number per case was 2 
(range, 1–7), and the median MET/CEP7 per case was 
1.05 (range, 1.00–1.76). Using our above-defined 
criteria for MET copy number gain and amplification, 
16.9% (67/335) of the cases harbored copy number 
gain, whereas none harbored amplification (Table 2). 
 
Table 2. MET gene copy number variation of HNSCC. 
Category Definition No. of 
cases 
Percentag
e (%) 
Negative Disomy  268 67.7 
Copy 
number gain 
2 < MET signals < 5 per nucleus in 20% or 
more of tumor cells 
67 16.9 
Amplificatio
n 
MET signals ≥ 5 per nucleus in 20% or 
more of tumor cells 
0 0 
 
Relationship between c-Met protein 
expression and MET copy number variation  
Cases harboring copy number gains had 
significantly higher c-Met protein expression levels 
than did cases without copy number gains (Fig. 2B; P 
= 0.001). According to a receiver operating 
characteristic curve analysis of MET copy number 
gain, an H-score of 65, which was higher than the 
above-mentioned mean and median c-Met expression 
H-score scores for overall HNSCC cases, was 
identified as the cut-off value for high c-Met protein 
expression (Fig. 2C). Using this cut-off value, 41.9% 
(166/396) of HNSCC cases exhibited high c-Met 
expression. 
Associations of a high c-Met protein 
expression level and MET copy number gain 
with clinicopathologic variables 
 Among the overall cohort of HNSCC cases, a 
high c-Met protein expression was not found to 
associate significantly with clinicopathologic 
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variables such as age, sex, smoking, anatomic site, 
HPV (p16 immunohistochemistry) status, 
lymphovascular invasion, perineural invasion, pT 
category, or pN category. No other significant 
associations were observed between MET copy 
number gain and other clinicopathologic variables 
(Table 3). 
Associations of a high c-Met protein 
expression level and MET copy number gain 
with patient survival 
 In the overall cohort, high c-Met protein 
expression tended to associate with inferior overall 
survival with marginal significance (P = 0.071; Fig. 
3A; supplementary Table 1). However, MET copy 
number gain was not related to overall survival 
(supplementary Table 1). Furthermore, neither c-Met 
protein expression nor MET copy number gain 
associated significantly with progression-free survival 
(supplementary Table 2). Other clinicopathologic 
variables, particularly age, anatomical site, p16 
expression, pT category, and pN category, were found 
to associate significantly with both overall and 
progression-free survival (supplementary Tables 1 
and 2).  
 Among the 305 cases in which complete tumor 
resection (R0 resection) was achieved, high c-Met 
expression was significantly related to inferior overall 
survival (P = 0.037; Fig. 3B and Table 4). In a 
multivariate Cox proportional hazards analysis, high 
c-Met expression tended to correlate independently 
with inferior OS, albeit with marginal significance (P 
= 0.061; Table 4). However, no significant association 
was observed between high c-Met expression and 
progression-free survival (Table 5). In addition, MET 
copy number gain did not associate significantly with 
overall or progression-free survival among cases 
involving R0 resection (Table 4 and 5). In this 
subgroup, other clinicopathologic variables, 
particularly anatomical site, pT category, and pN 
category, associated significantly with overall 
survival and progression-free survival (Table 4 and 5). 
 
 
Figure 3. Kaplan–Meier analysis of overall survival according to c-Met 
expression status. In the overall cohort of head and neck squamous cell carcinoma 
(HNSCC) cases, a high c-Met protein expression level tended to correlate with 
inferior overall survival in a marginally significant relationship (A). Among HNSCC 
cases that achieved complete (R0) resection, a high c-MET protein expression level 
correlated significantly with inferior overall survival (B). 
 
Table 3. Clinicopathologic characteristics of HNSCC according to the c-MET protein expression and MET gene CN gain status. 
 Category Variables No. of cases  
(n = 396) 
c-MET protein No. of cases  
(n = 335) 
MET copy number variation 
Low (%) High (%) P-value No gain (%) CN gain (%) P-value 
(n = 230) (n = 166) (n = 268) (n = 67) 
Sex Male 298 180 (78.3) 118 (71.1) 0.102 80 65 (24.3) 15 (22.4) 0.749 
 Female 98 50 (21.7) 48 (28.9)  255 203 (75.7) 52 (77.6)  
Age (yrs) < 58 194 111 (48.3) 83 (50.0) 0.733 167 129 (48.1) 38 (56.7) 0.209 
 ≥ 58 202 119 (51.7) 83 (50.0)  168 139 (51.9) 29 (43.3)  
Smoking Never smoker 154 88 (38.3) 66 (39.8) 0.924 128 106 (39.6) 22 (32.8) 0.161 
 Ex-smoker 80 46 (20.0) 34 (20.5)  66 56 (20.9) 10 (14.9)  
 Current smoker 162 96 (41.7) 66 (39.8)  141 106 (39.6) 35 (52.2)  
Anatomical sites Oral cavity 204 110 (47.8) 94 (56.6) 0.305 168 129 (48.1) 39 (58.2) 0.164 
 Oropharynx 122 76 (33.0) 46 (27.7)  109 94 (35.1) 15 (22.4)  
 Hypopharynx 28 16 (7.0) 12 (7.2)  24 17 (6.3) 7 (10.4)  
 Larynx 42 28 (12.2) 14 (8.4)  34 28 (10.4) 6 (9.0)  
p16 IHC status Negative 236 134 (58.3) 102 (61.4) 0.524 190 149 (55.6) 41 (61.2) 0.408 
 Positive 160 96 (41.7) 64 (38.6)  145 119 (44.4) 26 (38.8)  
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 Category Variables No. of cases  
(n = 396) 
c-MET protein No. of cases  
(n = 335) 
MET copy number variation 
Low (%) High (%) P-value No gain (%) CN gain (%) P-value 
(n = 230) (n = 166) (n = 268) (n = 67) 
Lymphovascular invasion Negative 320 182 (79.1) 138 (83.1) 0.318 267 208 (77.6) 59 (88.1) 0.057 
 Positive 76 48 (20.9) 28 (16.9)  68 60 (22.4) 8 (11.9)  
Perineural invasion Negative 342 202 (87.8) 140 (84.3) 0.318 285 226 (84.3) 59 (88.1) 0.443 
 Positive 54 28 (12.2) 26 (15.7)  50 42 (15.7) 8 (11.9)  
Resection margin status R0* 305 175 (76.1) 130 (78.3) 0.630 255 202 (75.4) 53 (79.1) 0.522 
 Non-R0 91 55 (23.9) 36 (21.7)  80 66 (24.6) 14 (20.9)  
Pathologic T stage pT1-2 326 188 (81.7) 138 (83.1) 0.720 273 218 (81.3) 55 (82.1) 0.888 
 pT3-4 70 42 (18.3) 28 (16.9)  62 50 (18.7) 12 (17.9)  
Pathologic N stage pN0-1 248 144 (62.6) 104 (62.7) 0.993 204 156 (58.2) 48 (71.6) 0.044 
 pN2-3 148 86 (37.4) 62 (37.3)  131 112 (41.8) 19 (28.4)  
HNSCC: head and neck squamous cell carcinoma; CN: copy number; IHC: immunohistochemistry 
* R0 resection status was defined as complete tumor resection 
 
Table 4. Cox analysis for overall survival among complete tumor resection (R0 resection; n=305). 
Category Variables Univariate Multivariate 
HR (95% CI) P-value HR (95% CI) P-value 
Sex Female 1  N/A  
 Male 1.242 (0.681-2.265) 0.480 N/A  
Age (years) < 58 1  1  
 ≥ 58 1.881 (1.048-3.493) 0.034 1.752 (0.953-3.220) 0.071 
Location Oropharynx 1  1  
 Oral cavity 2.654 (1.118-6.302) 0.027 3.570 (1.436-8.871) 0.006 
 Hypopharynx 3.225 (0.806-12.9) 0.098 2.377 (0.587-9.623) 0.225 
 Larynx 1.830 (0.457-7.319) 0.393 2.526 (0.613-10.418) 0.200 
Smoking Never smoker 1  N/A  
 Ex-smoker 0.621 (0.250-1.538) 0.303 N/A  
 Current smoker 1.157 (0.631-2.120) 0.637 N/A  
p16 IHC status  1  N/A  
  1.457 (0.782-2.717) 0.236 N/A  
Lymphovascular invasion Absent 1  N/A  
 Present 1.795 (0.913-3.528) 0.090 N/A  
Perineural invasion Absent 1  N/A  
 Present 1.877 (0.907-3.882) 0.090 N/A  
Pathologic T stage pT1-2 1  1  
 pT3-4 4.089 (2.240-7.464) < 0.001 2.714 (1.413-5.214) 0.003 
Pathologic N stage pN0-1 1  1  
 pN2-3 2.198 (1.248-3.872) 0.006 2.263 (1.187-4.315) 0.013 
c-MET expression Low 1  1  
 High 1.838 (1.037-3.259) 0.037 1.742 (0.975-3.112) 0.061 
MET CN gain No gain 1  N/A  
 Gain 0.577 (0.244-1.366) 0.211 N/A  
HNSCC: head and neck squamous cell carcinoma; CN: copy number; IHC: immunohistochemistry. 
 
Table 5. Cox analysis for progression-free survival among complete tumor resection (R0 resection; n=305). 
Category Variables Univariate Multivariate 
HR (95% CI) P-value HR (95% CI) P-value 
Sex Female 1  N/A  
 Male 1.007 (1.107-1.671) 0.977 N/A  
Age (years) < 58 1  1  
 ≥ 58 1.767 (1.048-2.819) 0.017 1.635 (0.998-2.679) 0.051 
Location Oropharynx 1  1  
 Oral cavity 2.159 (1.126-4.140) 0.020 2.386 (1.100-5.176) 0.028 
 Hypopharynx 3.270 (1.135-9.416) 0.028 2.352 (0.755-7.328) 0.140 
 Larynx 1.976 (0.730-5.347) 0.180 1.876 (0.620-5.679) 0.265 
Smoking Never smoker 1  N/A  
 Ex-smoker 0.879 (0.436-1.774) 0.720 N/A  
 Current smoker 1.563 (0.948-2.577) 0.080 N/A  
p16 IHC status  1  1  
  1.812 (1.075-3.053) 0.026 0.635 (0.353-1.140) 0.128 
Lymphovascular invasion Absent 1  1  
 Present 1.885 (1.094-3.249) 0.022 1.811 (0.998-3.286) 0.051 
Perineural invasion Absent 1  1  
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Category Variables Univariate Multivariate 
HR (95% CI) P-value HR (95% CI) P-value 
 Present 2.060 (1.168-3.634) 0.013 1.219 (0.639-2.323) 0.548 
Pathologic T stage pT1-2 1  1  
 pT3-4 3.328 (2.003-5.529) < 0.001 2.290 (1.307-4.014) 0.004 
Pathologic N stage pN0-1 1  1  
 pN2-3 1.969 (1.247-3.110) 0.004 1.842 (1.055-3.215) 0.032 
c-MET expression Low 1  N/A  
 High 1.186 (0.750-1.874) 0.466 N/A  
MET CN gain No gain 1  N/A  
 Gain 0.494 (0.235-1.037) 0.062 N/A  
HNSCC: head and neck squamous cell carcinoma; CN: copy number; IHC: immunohistochemistry. 
 
Discussion 
 Although several studies have evaluated c-Met 
expression levels and MET amplification/copy 
number alteration in several types of cancer, none 
have determined cut-off values for these parameters 
with regard to prognostic importance or patient 
selection for MET inhibitor therapy [13, 17-19, 31-36]. 
In this study, we aimed to investigate changes in 
statuses of c-Met protein expression and MET copy 
number, to analyze the association between these 
factors, and to determine the prognostic value of both 
factors in patients with HNSCC. 
 Previous studies of c-Met expression and MET 
copy number alteration in HNSCC have been 
restricted to specific anatomic sites or stage, or have 
included relatively small numbers of cases; in 
addition, the studies were heterogeneous with respect 
to detection method or treatment modality [13, 17-19]. 
These differences might explain the lack of 
confirmation for the prognostic significance of c-Met 
expression or MET copy alteration or cut-off values 
for these factors. In addition, MET amplification or 
copy number alteration has been rarely studied in 
HNSCC, particularly in cohorts composed primarily 
of patients treated with radical surgery. In contrast, 
the current study presents a robust evaluation of 
c-Met expression and MET copy number alterations in 
a large number of HNSCC cases that occurred in 
various anatomic sites of the head and neck; in 
addition, all involved patients underwent surgical 
resection with a curative aim and standard adjuvant 
chemoradiotherapy according to indicated treatment 
protocols.  
 In the present cohort of HNSCC cases, overall 
c-Met protein expression was variable, with an 
average H-score of approximately 60 (scale: 0–300). 
The c-Met expression level differed according to 
anatomical site, with lower and higher levels 
observed in laryngeal SCC and SCC of the oral cavity, 
respectively, and intermediate levels in 
oropharyngeal and hypopharyngeal SCC. These 
findings agree with a previous study in which high 
c-Met expression was relatively more frequent in the 
oral cavity and less frequent in the larynx [18], 
although the previous study involved a relatively 
smaller cohort and somewhat different detection 
criteria. Although little is known about other 
comparative analyses of c-Met expression according 
to anatomical site, it appears that SCC of the oral 
cavity might be associated with high c-Met expression 
more strongly than HNSCCs at other anatomical sites.  
Differences in tumor microenvironment, 
according to various anatomical sites of HNSCC, 
might be related to different expression levels of 
c-Met. Active immune responses against foreign 
bodies occur in the oral cavity, while HPV infection is 
predominantly found in oropharyngeal areas. This 
might suggest a difference in immune responses 
according to anatomical site, which may be associated 
with differential c-Met expression. Hepatocyte 
growth factor (HGF), a ligand of Met, plays a 
significant role in immune surveillance in HNSCC 
[37]. In addition to tumor microenvironment, 
tumor-intrinsic factors, such as invasion, metastasis, 
and cancer stem cell-like phenotype, may also 
contribute to differences in c-Met expression. Several 
studies have shown that HGF/Met signaling is 
involved in tumor invasion, migration, and 
metastasis, as well as cancer stem cell-like properties 
[37]. Therefore, anatomical sites of HNSCC should be 
considered when choosing candidates in 
c-Met-associated clinical trials. Further study is 
needed to identify potential mechanisms of variances 
in c-Met expression at different anatomical sites.  
 Regarding MET alteration, a copy number gain 
was observed in 20.0% (67/335) of the tested cases in 
the present study. A majority (80.0% of tested cases, 
268/335) of the remaining HNSCC cases exhibited 
normal disomy of MET and chromosome 7. In 
addition, no MET amplification was observed in the 
present study. In previous studies, high-level or focal 
MET amplification (clustered MET signals) has been 
reported as a rare event in HNSCC, as well as in other 
type of cancers (e.g., non-small-cell lung cancer or 
gastric cancer), with rates ranging 1–8%, despite 
considerable differences among studies in the 
detection methods and criteria used to define high 
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copy number [19, 32, 33, 36]. Although MET 
amplification may be rare, MET copy number gain 
may not be an uncommon event in HNSCC.  
 HNSCC cases harboring a MET copy number 
gain had significantly higher c-Met protein expression 
levels than did cases with a normal MET status, 
suggesting a potential association between a MET 
gain and c-Met protein overexpression. This 
corroborates earlier studies that reported positive 
correlations of c-Met expression (via 
immunohistochemistry) with MET copy number gain 
or amplification (via fluorescence in situ 
hybridization) [32, 33]. To further explore this result, a 
c-Met expression cut-off value of an H-score of 65, 
was determined based on the MET gain status. As 
noted previously, this value was slightly higher than 
the mean and median c-Met expression levels among 
all tested HNSCC cases, which would generally be 
used as a cut-off value with which to determine a high 
value for a quantitative variable.  
 High c-Met expression, determined through a 
MET gain-based analysis, was significantly related to 
a poor overall survival rate and tended to be 
independently related to poor overall survival among 
cases with R0 resection. In other words, a high tumor 
c-Met expression level might be associated with 
high-risk HNSCC even after complete tumor removal. 
According to the findings of the present study, the 
devised method for determining high c-Met 
expression according to a MET gain-based analysis 
appears to be reliable and appropriate for the 
prediction of patients with high-risk HNSCC. 
 Recent studies of potential biomarkers to 
identify patients who would benefit from MET 
pathway inhibitors suggest a 50% cut-off for c-Met 
expression. In other words, ≥ 50% of tumor cells 
would exhibit moderate (2+) to strong (3+) intensity 
in a c-Met immunohistochemistry analysis (i.e., H 
score ≥100) or 1+ or stronger staining (i.e., H score ≥
50). Although those trials have focused on 
non-small-cell lung cancer and gastric or 
esophagogastric junction adenocarcinoma [34-36], the 
c-Met expression cutoff value determined in the 
present study could be considered when developing 
biomarkers to select patients with HNSCC who 
would benefit from MET inhibitor therapy.  
 A MET gain or increased copy number did not 
directly associate with the survival prognoses of 
HNSCC patients in the present study. As in previous 
studies, the prognostic role of a MET gain has not yet 
been confirmed in HNSCC [19], although other 
studies have identified a relationship between a MET 
gain and poor prognosis in patients with lung, gastric, 
or nasopharyngeal carcinoma [27-29, 32]. Regardless 
of differences in the detection methods, interpretation 
criteria, and tumor types between the present study 
and previous studies, a MET gain itself did not seem 
to affect patient prognosis among patients with 
HNSCC who underwent curative surgical resection. 
In summary, SCC of the oral cavity was 
associated with higher c-Met protein expression when 
compared with HNSCCs of other anatomical sites, 
and the c-Met protein expression level was associated 
with a MET gain. Furthermore, a high c-Met 
expression level, determined according to the MET 
gain status, was found to correlate with inferior 
overall survival, especially in patients who had 
achieved complete resection of HNSCC. The method 
described herein for determining high c-Met 
expression based on MET gains seemed to be reliable 
and appropriate for predicting patients with high-risk 
HNSCC and could facilitate the selection of patients 
who would benefit from MET inhibitor therapy. 
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